Program
Octreotide
Also written as “Sandostatin LAR Depot”, “Octreotide LAR” and “Sandostatin LAR”.
Its studies are mostly in Acromegaly · Obesity · Diarrhea · Malignant Carcinoid Syndrome · Thymoma, led by 5 companies.
Drug pageOctreotide: every studyMany companies study it; this page follows only the 30 they lead. All 121 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 210 open or running | phase 4since Dec 17, 2002 | Nov 2, 1999 | none ahead |
| Keenova Therapeuticsits history only | 40 open or running | phase 3since Sep 30, 2008 | Sep 30, 2008 | none ahead |
| Chiesi Farmaceutici | 30 open or running | phase 3since Aug 5, 2011 | Aug 5, 2011 | none ahead |
| Ambrilia Biopharmaits history only | 10 open or running | phase 3since Mar 21, 2008 | Mar 21, 2008 | none ahead |
| Dauntless Pharmaceuticalsits history only | 10 open or running | phase 1since Jan 17, 2017 | Jan 17, 2017 | none ahead |
Also a collaborator on its studies: Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chiesi Farmaceutici only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 5, 2011First study: phase 3 study in AcromegalyFirst studyNCT01412424 · 155 enrolled · United States, Germany, Hungary and more
- Jan 28, 2016Phase 3 study in AcromegalyNCT02685709 · 146 enrolled · United States, Austria, France and more
- Aug 10, 2017Phase 3 study in AcromegalyNCT03252353 · 56 enrolled · United States, Australia, Bulgaria and more
TargetBeta
“Somatostatin receptor agonist”ChEMBL 37, by rule
Studies
All 3 Chiesi Farmaceutici leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03252353Acromegaly · United States, Australia, Bulgaria and more | 3 | UNKNOWN | Jun 13, 2019 | 56 |
| NCT02685709Acromegaly · United States, Austria, France and more | 3 | Completed | Oct 2020 | 146 |
| NCT01412424Acromegaly · United States, Germany, Hungary and more | 3 | Completed | May 2014 | 155 |
How it is read
Names in the registry
- “Octreotide”, 9 entries
- “Sandostatin LAR Depot”, 3 entries
- “Octreotide LAR”, 3 entries
- “Sandostatin LAR”, 3 entries
- “Octreotide capsules”, 2 entries
Conditions, from the studies’ own filings
- Acromegaly, 17 studies
- Obesity, 2 studies
- Diarrhea, 2 studies
- Malignant Carcinoid Syndrome, 1 study
- Thymoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.